Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis

Chemotherapy

Volumn 48, Issue 2, 2002, Pages 100-108

  Roos, K ^a   Brunswig Pitschner, C ^b   Kostrica, R ^c   Pietola, M ^d   Leroy, B ^e   Rangaraju, M ^e   Boutalbi, Y ^e  

^a Capio AB   (Sweden)

^b Private Practice for Urology   (Germany)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d Laakso Hospital   (Finland)

^e SANOFI   (France)

Author keywords

Acute maxillary sinusitis; HMR 3647; Ketolide; Telithromycin

Indexed keywords

TELITHROMYCIN;

ADULT; AGED; ARTICLE; BACTERIUM ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXILLA SINUSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; X RAY;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KETOLIDES; MACROLIDES; MALE; MAXILLARY SINUSITIS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0036249139     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057670     Document Type: Article

References (32)

1. Sinusitis: Bench to bedside: Current findings, future directions
2. Prevalence of selected chronic conditions: United States 1986-1988
3. Current estimates from the National Health Interview Survey, 1992
4. Current diagnosis and management of sinusitis
5. IDCP guidelines: Management of upper respiratory tract infections
6. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998
7. The Alexander project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
8. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study
9. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), a lincosamide (clindamycin)
10. In vitro study of the minimal inhibitory concentrations (MIC) of telithromycin (HMR 3647), macrolides and quinolones against Haemophilus, Streptococcus, Staphylococcus and Moraxella strains obtained from upper and lower respiratory tract infections and from maxillary sinus aspiration
11. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
12. Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay
13. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany
14. In vitro activity of the new ketolide antibiotic HMR 3647 against Gram-positive bacteria
15. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae
16. B resistance induction by the ketolide telithromycin (HMR 3647): Role of the 3-keto group
17. Pharmacokinetics of 800 mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers
18. Pharmacokinetic study of a new ketolide antimicrobial telithromycin (HMR 3647) in otorhinolaryngology
19. Low dosage and long treatment duration of beta-lactam: Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae
20. Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis
21. Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: A multicenter, double-blind, randomized study
22. Cephalosporin treatment of maxillary sinusitis
23. Comparative evaluation of cefuroxime axetil and cefaclor for treatment of acute bacterial maxillary sinusitis
24. Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults
25. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute exacerbations of chronic bronchitis in patients with COPD
26. Efficacy of telithromycin (HMR 3647), a new once-daily antimicrobial, in the treatment of community-acquired pneumonia
27. Efficacy and tolerability of telithromycin (HMR 3647) vs high-dose amoxicillin in the treatment of community-acquired pneumonia
28. Efficacy of 5 days' telithromycin (HMR 3647) vs 10 days' penicillin V in the treatment of pharyngitis in adults
29. Oral telithromycin (HMR 3647) 800 mg once daily for 5 days is well tolerated and as effective as oral clarithromycin 250 mg twice daily for 10 days in group A β-hemolytic streptococcal (GABHS) pharyngitis/tonsilitis
30. Oral telithromycin (HMR 3647) 800 mg once daily is well tolerated and as effective as oral clarithromycin 500 mg twice daily in community-acquired pneumonia (CAP) in adults
31. Oral telithromycin (HMR 3647) 800 mg once daily for 5 days and 10 days is well tolerated and as effective as amoxicillin/clavulanic acid 500/125 mg three-times daily for 10 days in acute maxillary sinusitis (AMS) in adults